Navigation Links
ChromaDex Licenses Green Chemistry Technology to Manufacture a New Class of Super Fruit Compounds

Anthocyanins, leucoanthocyanidins and anthocyanidins are natural,

plant-based colorants with strong antioxidant properties

IRVINE, Calif., July 21 /PRNewswire-FirstCall/ -- ChromaDex Corp., (OTC Bulletin Board: CDXC) a leader in phytochemical reference standards and contract research, announced today its wholly owned subsidiary has entered into a world-wide license agreement with The Research Foundation of the State University of New York, on behalf of the University at Buffalo (SUNY Buffalo), to produce and market three classes of plant-based ingredients for nutraceutical, functional food, beverage, natural chemical, cosmetic and pharmaceutical industries. Under the terms of the agreement, ChromaDex made an up-front cash payment to SUNY Buffalo and will pay earned royalties on sales of covered technology products and services.

"Anthocyanins are botanically-derived compounds that represent the next 'super fruit' class of phytochemical ingredients," said Frank L. Jaksch Jr., co-founder and CEO of ChromaDex. "This novel and 'green' technology will enable ChromaDex to selectively and cost-effectively manufacture these ingredients and make them commercially available for the first time."

'Green' Ingredients

The technology licensed to ChromaDex includes methods to selectively manufacture anthocyanins, leucoanthocyanidins and anthocyanidins, which are naturally occurring pigments and antioxidants that can be used as natural colorants and may also aid in controlling blood glucose levels to assist with weight management and conditions such as diabetes. Like resveratrol, a super fruit compound that has created extraordinary excitement, anthocyanins are also found in red wine and are even more likely to be responsible for the "French paradox."

"We have been able to develop these molecules for the first time through a proprietary application," said Dr. Mattheos Koffas, assistant professor of chemical engineering at SUNY Buffalo. "While all plants produce anthocyanins, they are challenging to extract and study in well-defined mixtures. Now that we can harvest them from a lab, they can be further studied for their antioxidant and other properties in various indications, especially ones related to the treatment of the metabolic syndrome, i.e. chronic pathological conditions stemming from obesity."

ChromaDex plans to market these new, natural ingredients to food, beverage, pharmaceutical and supplement manufacturers in order to meet the growing demands for natural, plant-based ingredients in the marketplace. The company will also evaluate opportunities to partner the ingredients for expanded applications.

Under the terms of the agreement, ChromaDex agreed to pay an annual minimum royalty payment to SUNY Buffalo and a milestone payment upon sale of the first licensed product, licensed service or sublicense fee payment received by ChromaDex. With the consent of SUNY Buffalo, ChromaDex may also grant sublicenses to third parties and has agreed to reimburse SUNY Buffalo for certain patent costs related to the licensed patents.

About ChromaDex

ChromaDex is a world leader in the development of Phytochemical and Botanical Reference Standards and the creation of associated intellectual property. ChromaDex is committed to sustainable "Green chemistry" and provides the dietary supplement, food, beverage, nutraceutical and cosmetic industries with the analytical tools and services to meet product regulatory, quality, efficacy and safety standards.

Forward-Looking Statements

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to ability to market, produce and sell the referenced ingredients, risks relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

SOURCE ChromaDex Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
2. Sanofi-Aventis renews licenses for Genomatix chip analysis pipeline
3. NuVasive Licenses Its Insert and Rotate Technology
4. GeneGo Licenses MetaCore Data Analysis Suite to AVEO Pharmaceuticals
5. Optherion Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostics Based on Chromosome 10 Genetic Variations
6. Quest Diagnostics Licenses Technology Underlying SensiTrop(TM) HIV Co-Receptor Tropism Test from Pathway Diagnostics
7. HealthTek Software Solutions Licenses First DataBanks OrderView Med Knowledge Base(TM) to Streamline Medication Selection, Management and Reconciliation
8. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
9. SuperArray Bioscience Corporation Licenses RNA Interference Patent From The Carnegie Institution
10. Cyberonics Licenses Obesity-Related Patents
11. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... ... Sclerosis Complex (TSC), as well as raising public awareness of the disorder while ... it—presented a third donation of $35,000 to bolster progress at the Tuberous Sclerosis ...
(Date:11/24/2015)... , ... November 25, 2015 , ... ... monitoring. Their Care Plan software creates an agreement between the practice owner ... plan, including financial, scheduling, monitoring, notification, and projections. Click here ...
(Date:11/24/2015)... AZ (PRWEB) , ... November 24, 2015 , ... Young ... 2.0™ treatments from Dr. Angela Wolfman and Dr. Kedar S. Lele, who are ... for frenectomies, cavities and fillings, the WaterLase iPlus 2.0™ system causes minimal discomfort and ...
(Date:11/24/2015)... ... 25, 2015 , ... Catalent Pharma Solutions, the leading global ... and global clinical supply services, today announced that Dr. Christine Milligan, Global Director, ... Conference, to be held at the InterContinental Seoul COEX Hotel, Seoul, Republic of ...
(Date:11/24/2015)... ... 24, 2015 , ... It takes only three to five seconds to make ... the first impression be positive and reflects business values. If a client starts with ... want to return. They will also share their thoughts about a business with others, ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 Research ... of the "Membranes Market - Global Forecast to ... Asia-Pacific , accounting for 37.21% of the ... Asia-Pacific region is projected to ... This growth has been attributed primarily to the fast ...
(Date:11/24/2015)... 24, 2015  Thanks to a donor with a ... Medical Center,s Sister Diane Grassilli Center for Women,s Health ... San Francisco . ... forward with a gift of $617,320 that allowed the ... with Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, three-dimensional (3-D) ...
(Date:11/24/2015)... Nueva York , 24 de ... (ABD), fabricante del Avery Breathing Pacemaker System, se ... , MD; Ph.D. como consultor clínico. ... --> Foto -   ... El doctor Jonzon es un fisiólogo y consultor ...
Breaking Medicine Technology: